Whitehawk Therapeutics, Inc. Insider Trading

WHWK

Last 12 months

Insiders sold $2.58M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Executive Officer David James Lennon sold 900K on Apr 8, 33% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2021.

Net open-market

−$2.58M

0 buys · 9 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Aug 2021

Aug 26, 2021

Get an email when WHWK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Apr 15 – 16	Scott M. Giacobello Chief Financial Officer	SoldNo plan 2 parts	218,600	$4.03 average	882K	43%	Form 4
Apr 13 – 14	Bryan Ball See remarks	SoldNo plan 2 parts	118,849	$3.60 average	428K	23%	Form 4
Apr 9 – 10	Bryan Ball See remarks	SoldNo plan 2 parts	56,596	$3.55 average	201K	9.9%	Form 4
Apr 9	David James Lennon Chief Executive Officer	SoldNo plan	14,500	$3.38	49K	2.7%	Form 4
Apr 6 – 8	David James Lennon Chief Executive Officer	SoldNo plan 3 parts	260,427	$3.45 average	900K	33%	Form 4
Apr 2	David James Lennon Chief Executive Officer	SoldNo plan	26,858	$3.48	93K	3.3%	Form 4
Mar 2	David James Lennon Chief Executive Officer	SoldNo plan	5,100	$3.31	17K	10%	Form 4
Mar 2	Bryan Ball See remarks	SoldNo plan	1,834	$3.31	6K	0.9%	Form 4
Mar 2	Scott M. Giacobello Chief Financial Officer	SoldNo plan	2,594	$3.31	9K	8.5%	Form 4
Mar 3, 2025	Bryan Ball See remarks	SoldNo plan	2,147	$2.35	5K	1.0%	Form 4
Mar 3, 2025	Scott M. Giacobello Chief Financial Officer	SoldNo plan	2,806	$2.35	7K	10%	Form 4
Mar 3, 2025	David James Lennon Chief Executive Officer	SoldNo plan	5,690	$2.35	13K	15%	Form 4

Apr 15 – 16No plan
Scott M. Giacobello
Chief Financial Officer · sold 218,600 at avg $4.03
882K
43% of stake
Apr 13 – 14No plan
Bryan Ball
See remarks · sold 118,849 at avg $3.60
428K
23% of stake
Apr 9 – 10No plan
Bryan Ball
See remarks · sold 56,596 at avg $3.55
201K
9.9% of stake
Apr 9No plan
David James Lennon
Chief Executive Officer · sold 14,500 at $3.38
49K
2.7% of stake
Apr 6 – 8No plan
David James Lennon
Chief Executive Officer · sold 260,427 at avg $3.45
900K
33% of stake
Apr 2No plan
David James Lennon
Chief Executive Officer · sold 26,858 at $3.48
93K
3.3% of stake
Mar 2No plan
David James Lennon
Chief Executive Officer · sold 5,100 at $3.31
17K
10% of stake
Mar 2No plan
Bryan Ball
See remarks · sold 1,834 at $3.31
6K
0.9% of stake
Mar 2No plan
Scott M. Giacobello
Chief Financial Officer · sold 2,594 at $3.31
9K
8.5% of stake
Mar 3, 2025No plan
Bryan Ball
See remarks · sold 2,147 at $2.35
5K
1.0% of stake
Mar 3, 2025No plan
Scott M. Giacobello
Chief Financial Officer · sold 2,806 at $2.35
7K
10% of stake
Mar 3, 2025No plan
David James Lennon
Chief Executive Officer · sold 5,690 at $2.35
13K
15% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch WHWK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with WHWK

CompareIntrinsic value

PRPHProPhase Labs Inc.

$0.01-42.00%0

RPRXRoyalty Pharma plc

$67.56+1.75%19

ORGOOrganogenesis Holdings Inc.

$0.87+4.19%50

LFVNLifeVantage Corporation

$5.97+3.65%73

CPRXCatalyst Pharmaceuticals Inc.

No recent price73

PAHCPhibro Animal Health Corporation

$39.43+4.73%57

ORMPOramed Pharmaceuticals Inc.

$4.13+3.25%35

REGNRegeneron Pharmaceuticals, Inc.

$930.67-4.39%54

Held by ETFs

WHWK is in 1 US ETF. The largest of them, with WHWK's weight in each:

iShares Micro-Cap ETFIWC0.04%of the fund

Spot a number that looks wrong? Check it in WHWK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing WHWK

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.